ImmunoCellular Therapeutics (IMUC) Stock: Climbing On Milestone Achievement

0
ImmunoCellular Therapeutics Ltd IMUC Stock News

ImmunoCellular Therapeutics Ltd IMUC Stock NewsImmunoCellular Therapeutics Ltd (NYSEAMERICAN: IMUC) is having an overwhelmingly positive start to the trading session this morning after announcing that it has achieved a key milestone surrounding the transfer of the selected T cell receptor genetic material into human hematopoietic stem cells. The news was overwhelmingly positive, exciting investors and sending the stock on a run for the top. Today, we’ll talk about:

  • The milestone achievement;
  • what we’re seeing from IMUC;
  • and what we’ll be watching for ahead.

IMUC Reaches Key Milestone

As mentioned above, ImmunoCellular Therapeutics is having an incredible start to the trading session this morning after announcing that it has achieved a key milestone. In a press release issued early this morning, the company announced that it has been able to verify the successful transfer of the selected T cell receptor genetic material into human hematopoietic stem cells. In the release, IMUC said that this milestone is a key step in validating the Stem-to-T-Cell approach to treatment.

As a result of the milestone, the company intends on moving forward with preclinical testing of its Stem-to-T-Cell technology. This technology was created to stimulate the patient’s immune system to produce an unlimited supply of killer T cells that specifically target and destroy tumor cells with minimal side effects. In a statement, Steven J. Swanson, PhD, Senior Vice President of Research at IMUC, had the following to offer:




We are excited to have achieved this critical next milestone in our Stem-to-T-Cell program, and are excited to begin the preclinical animal testing that can lay the foundation for potentially proceeding toward conducting human clinical trials… We and our collaborators are now working to design and implement the necessary animal studies to complete our proof-of-concept work. Our vision is to develop solutions for intractable cancers, extend the lives of cancer patients, and provide hope for a potential cure. We believe that our Stem-to-T-Cell program is potentially a game-changing treatment for cancer, and could be effective in treating many types of cancers.

The above statement was followed up by Anthony J. Gringeri, PhD, President and CEO at ImmunoCellular Therapeutics. Here’s what he had to offer:

We are pleased with the productivity and achievements to date of our research team and the continued generation of scientific validation of our Stem-to-T-Cell program. Continued testing of our novel immuno-oncology technology may elucidate how it can be applied in a real-world therapeutic setting, and lead the way toward conducting clinical trials, including potential exploration of combination with other approaches. From a corporate perspective, we are pleased with our ability to achieve our research goals while continuing to operate in a cost-efficient manner. We are also continuing to explore potential collaborations for our clinical programs and other strategic alternatives for our Company.

What We’re Seeing from The StockĀ 

One of the first lessons that we learn when we start to dabble in the market is that the news causes moves. In this particular case, the news released proved to be overwhelmingly positive. While it is still very early here, the Stem-to-T-Cell technology seems to be doing well in these very early stages. If all goes well, this could be a massive game changer for the oncology space. So, it’s no surprise to see that the stock is making a run for the top. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:39), IMUC is trading at $0.28 per share after a gain of $0.04 per share or 17.66% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on IMUC. In particular, we’re interested in following the development of the company’s proprietary Stem-to-T-Cell technology and we’re hoping that this becomes the pivotal change that the oncology space is looking for. We know… wishful thinking, but this could be big. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.